‘Difficult and challenging': Consultations on Red Dress Alert pilot project underway
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
9 minutes ago
- Globe and Mail
Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador
Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) today announced that Chris Webber, five-time NBA All-Star and Hall of Fame inductee, has joined the Company as the second official brand ambassador for Nugevia ™, Jupiter Neurosciences' new consumer longevity supplement line. Webber, who played 15 seasons in the National Basketball Association, including standout years with the Sacramento Kings, brings his championship mindset and commitment to peak performance to the Nugevia mission. Over his career, Webber was named NBA Rookie of the Year, earned five All-NBA selections, and left an indelible mark on the game with his skill, vision, and leadership. 'Chris embodies the principles at the core of Nugevia ™: longevity, resilience, and elite performance supported by real science,' said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. 'His dedication to preparation and his commitment to excellence both on and off the court make him an ideal advocate for our mission to help people look, feel, and perform their best at every stage of life.' Webber commented, 'In my playing days, staying at the top of my game took more than talent, it took discipline, recovery, and science-backed tools to keep my body and mind sharp. I'm a big believer in putting the right things in your body so you can keep giving your best, year after year. Nugevia's products aren't just another supplement, they're built on real clinical research and cutting-edge technology. Whether you're competing on the court, running a business, or just trying to keep up with your kids, Nugevia gives you that extra edge to perform at your peak.' Nugevia ™ is built on JOTROL ™, Jupiter's patented resveratrol-based micellar delivery platform that has demonstrated significantly enhanced bioavailability and underpins the Company's clinical-stage CNS therapies. The three debut formulations—GLO, MND, and PWR—are designed to support cellular resilience through intelligent stacking of synergistic ingredients, all enhanced for optimal absorption via the JOTROL ™ system. The Nugevia ™ brand reflects Jupiter's dual-path strategy, advancing clinically validated therapeutics while tapping into the rapidly growing longevity market, projected to reach $8 trillion by 2030. This consumer-facing arm is expected to create a revenue stream that supports ongoing clinical development, corporate operating costs, and enhances long-term shareholder value. A digital press kit, including high-resolution product imagery and key brand information, is available at About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia ™ product line. Both efforts are powered by JOTROL ™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, includeing indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website About JOTROL Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL ™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL ™ trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL ™ toward a Phase IIa trial in Parkinson's Disease. In addition to its therapeutic applications, JOTROL ™ serves as the foundation for Jupiter's Nugevia ™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia ™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the Company's ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 'approximates,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
CBC
10 minutes ago
- CBC
Holt Liberals projecting larger-than-forecast deficit this year
Social Sharing The Holt Liberal government is on track to run an even bigger budget deficit than projected in its first full year in power. The deficit is now projected to hit $668.7 million this year, almost $120 million more than Finance Minister René Legacy forecast in his first budget in March. That additional shortfall is because the government expects to spend $60 million more than planned this year, and to bring in $59.6 million less in revenue, according to a first-quarter fiscal update Legacy released Tuesday. The higher-than-expected spending includes $93.7 million in areas such as child welfare and youth services, social assistance, and seniors and long-term care, and $39.1 million in higher spending by regional health authorities. Those increases are partly offset by lower-than-predicted spending in some other areas. The decreased revenue includes a $16.2-million shortfall due to lower earnings at N.B. Power.
Globe and Mail
39 minutes ago
- Globe and Mail
As cancer rates increase for younger women, many choose to work during treatment
Sarah Mitchell, 44, was working full-time and going to school when she was diagnosed with breast cancer last fall. The single mother of two kids aged 8 and 10 dropped out of school right away, but decided to continue working through her six-month period of chemotherapy, which ended in March of this year. 'Part of it was that I needed some money to make ends meet,' she says, adding that housing costs in Victoria, where she lives, are very high and 'as a single income household, things are tight.' There are sickness benefits available to individuals facing cancer through federal Employment Insurance (EI), but they only cover 55 per cent of earnings up to a maximum of $695 a week, for 26 weeks. 'It's better than nothing, but it's not really enough to live on as a family of three,' Ms. Mitchell says. (Long-term disability benefits through Ms. Mitchell's employer wouldn't have kicked in until the EI benefits ran out, at 67 per cent of her salary.) Money wasn't the only reason Ms. Mitchell wanted to stay on the job. She says work was a huge help in keeping her mood in check. 'When you're not feeling well, you can focus on how you're not feeling well,' says Ms. Mitchell, who also continued to co-parent for her usual 50 per cent of the time. 'I needed to take my focus outside of myself.' Ms. Mitchell works in finance at a company that does leadership training, and says it helped that her employer was understanding on days she wasn't feeling well. She was able to work from home so she could do tasks from bed if she felt the need. 'I was just doing the bare bones of my job description [through chemo],' says Ms. Mitchell, who is now cancer-free but still feeling the effects of chemotherapy. 'Certain days after treatment that were just horrible,' she says, so 'If I needed a day [off]… I wouldn't work those days.' According to the Canadian Cancer Society, rates of cancer are higher for women than men among people under age 60. The sharpest rise in diagnosis rates is among women under 50, says Dr. Roochi Arora, a medical oncologist at Humber River Hospital in Toronto. A 2024 study out of the University of Ottawa examining Canadian data from the past 35 years showed an increase in rates of breast cancer diagnoses among women in their 20s, 30s and 40s. Dr. Arora, who says the majority of her patients are facing breast cancer, notes women are increasingly choosing to work during treatment. Some work to maintain normalcy and to avoid losing ground in their careers. Some work for monetary reasons and to maintain their work-provided health benefits at such a crucial time. 'Dual income is increasingly necessary in households, and many women have thriving careers they want to remain connected to even when going through cancer treatment.' Balancing a career and cancer at the same time is possible, she adds, but it helps if one plans ahead, sets realistic expectations and has job flexibility. Many patients' expenses go up when they get cancer, due to what Dr. Arora calls 'hidden costs' associated with dealing with an illness. They may need more help with their kids. They may have to pay for parking at hospitals on a weekly or bi-weekly basis. Some patients must pay for certain medications out-of-pocket as well. 'I can't tell you how many people are saying [that] EI barely covers anything,' she says. Hiding cancer while on the job Fear of loss of income or career repercussions may drive individuals living with cancer to conceal their condition and treatment from their employers. A 2023 study out of Memorial University in St. John's found that one in four of respondents – residents of Newfoundland and Labrador with a history of cancer – reported stigmatization due to their cancer history. A smaller number, one in seven respondents, said they had been discriminated against because of their cancer history. The study's authors said the most common sources contributing to those experiences were friends, insurance and financial companies and workplaces. Janice (who requested her last name be withheld due to fear of career repercussions) is a woman in her 60s living in the Greater Toronto Area. When Janice was diagnosed with breast cancer last year, she had breast-removal and reconstruction surgery without radiation or chemotherapy. When Janice was offered a new job shortly afterward, she took it, but decided not to disclose her cancer, even after she developed a 'massive infection' around her breast implant. She says her decision was partly because of a termination from a previous job that she attributed to ageism. Janice, who works in sales as an account manager, decided to keep working while hiding a vacuum dressing in her clothing – a contraption with a battery pack that covers the infected area and is attached to a pump with a hose. She said her device occasionally made sounds that she would disguise with a fake cough. 'I don't want the people I work with to change the way they look at me, the way they view me,' says Janice. 'It's my story.' If individuals want to continue working through cancer treatment, Dr. Arora says there are strategies they can try to help keep things manageable: Organizations can also help employees who are going through cancer better manage their lives, Dr. Arora adds. She recommends that employers be flexible about where and when an employee works, when possible, and consider lightening their employee's workload. Organizations should also offer all employees a benefits package that includes paid leave for illness. Interested in more perspectives about women in the workplace? Find all stories on The Globe Women's Collective hub here, and subscribe to the new Women and Work newsletter here. Have feedback? Email us at GWC@
